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a b s t r a c t
Aim of the study: The aim of this study is to evaluate standard scalp EEG ﬁndings in patients
with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease (AD).
Clinical rationale: PCA is a topographically selective variant of AD. Patients with typical AD
have an increased likelihood of seizures, which may negatively impact overall functional
performance and cognition. It is currently unknown what the typical EEG ﬁndings are for
patients with PCA.
Materials and methods: A retrospective chart review was performed on patients identiﬁed
either with autopsy conﬁrmed (n = 13) or clinically (n = 126) as PCA.
Results: 139 patients were included though only 23 (16.5%) had undergone EEG recording.
The EEG was normal in 6 (26%), while an abnormal EEG was present in 17 (74%). Interictal
epileptic discharges (IEDs) were found in 2 of the 23 patients (9%).
Conclusions: This study of limited sample size suggests that there may be an increased
predilection to ﬁnd IEDs within PCA when compared to typical AD. Larger cohorts are
required to determine frequency of abnormal EEGs in PCA, roles of AEDs in therapy, and in
the selection of preferred AED.
Clinical implications: Patients with PCAwould potentially beneﬁt from an EEG for assessment
of IEDs which may provide the clinician with a therapeutic opportunity.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.1. IntroductionAlzheimer's disease (AD) is a neurodegenerative condition
associated with an increased predisposition for seizures,
particularly within early onset populations [1,2]. Seizures* Corresponding author at: 4500 San Pablo Rd, Jacksonville, FL 32224, U
E-mail address: Goldstein.Eric@Mayo.edu (E.D. Goldstein).
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0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Smay be the presenting symptom of AD with several seizure
semiologies reported [3–6]. Patients with AD have an overall 6-
fold increased risk of ﬁrst time unprovoked seizure when
compared to healthy similarly-aged patients, and an estimat-
ed prevalence of 10–22% [7–9]. Posterior cortical atrophy (PCA)
is a syndromecharacterized by predominant visual deﬁcits notnited States.
p. z o.o. All rights reserved.
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memory and insight early in the disease [10,11]. The most
common neuropathologic etiology of PCA is AD with a
disproportionately greater burden of pathology in the posteri-
or cortical regions in PCA patients compared with typical
forms of AD [10,12]. It is thought that 5% of thosewithAD likely
have PCA [13–15], although the actual prevalence of PCA may
be higher due to the potential for under-diagnosis.
2. Clinical rationale for the studyThe routine use of scalp electroencephalography (EEG) within
memory clinics is not standardized, though there is evidence
that the presence of epileptic discharges may contribute
further to cognitive decline [16]. A previous study has
demonstrated that of those presenting to a memory disorders
clinic without known seizure disorder, 2% are noted to have
interictal epileptic discharges (IEDs) on scalp EEG, primarily of
temporal lobe origin [17]. The aim of this study is to describe
standard scalp EEG ﬁndings in patients with autopsy con-
ﬁrmed or clinically diagnosed PCA patients.3. Materials and methods
3.1. Study protocol and patients
A retrospective chart review was performed on patients
identiﬁed either with a neuropathologic diagnosis of posterior
AD (n = 13) or diagnosed clinically (n = 126) as PCA following
Institutional Review Board approval. Ethical approval was not
necessary for preparation of this article. The diagnostic criteria
for PCA have been previously published [10,15]. Those without
EEG during evaluation and pre-existing seizure disorder were
excluded from the study. Clinical data was obtained from
January 1990 through December 2017, including demographic[(Fig._1)TD$FIG]
Fig. 1 – Studyinformation, subjective onset of symptoms, scalp EEG descrip-
tions as read by electroencephalographers and antiepileptic
drug (AED) usage. Fig. 1 shows the study design.
3.2. Electroencephalography
Scalp EEGs were performed using a digital 21-channel
recording with the International 10–20 system for electrode
placement. Study duration varied between 30 and 80 min,
including activating procedures. All recordings were reviewed
using referential and bipolar montages. Each EEG was
interpreted by a board-certiﬁed clinical neurophysiologist.
IEDs were deﬁned according to the International Federation of
Clinical Neurophysiology [18].4. Results
4.1. Patients
A total of 139 patients with PCA were identiﬁed. Of these, only
23 (16.5%) had underwent EEG recording. One patient was
excluded due to pre-existing seizure disorder. Mean age of
subjective symptom onset was 58 years, with scalp EEG
obtained on average 2 years following onset. Eleven patients
died in the years following completion of their EEG, with a
mean age of death of 76 years old. A summary of patients'
characteristics is provided in Table 1.
4.2. Electroencephalography
The EEG was normal in 6 of the 23 patients (26%), while the
majority of studied patients had an abnormal EEG (17/23, 74%).
Sleep EEG was achieved in 19 of 23 patients (83%). Of the 17
subjects with abnormal EEGs, 13 (74%) had varying degrees of
generalized slowing, while 4 (26%) had focal slowing. Patients
with focal slowing were without hemispheric preference anddesign.
Table 1 – Clinical characteristics of the study subjects.
All (n = 23) Abnormal EEG (n = 17) Normal EEG (n = 6)
Male gender (%) 15 (65) 9 (52) 3 (50)
White (%) 22 (95) 17 (100) 1 (17)
Age at EEG, years 64  7.8 66  8.9 60  4
Subjective onset age, years 59  8.4 60  8.9 58  4
Onset to EEG, years 5  3.6 6  3.7 2  2
Age at death, mean (%) 76, 49% 77, 53% 71, 33%
EEG to death, years 6.9 7 6.5
Slowing of background rhythm
Generalized (%) 13 (57) 13 (74)
Focal (%) 4 (17) 4 (26)
Epileptic discharges 2 (9) 2 (12)
Sleep/Drowsiness Achieved 19 (83) 15 (88) 2 (33)
Benign variants 3 (13) 3 (18) 0 (0)
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onset and onset to EEG times. Of the 6 patients with normal
EEGs, only 1 was Caucasian (17%). Three patients had benign
EEG variants (13%).
IEDs were found in two patients (2/23, 9%). The ﬁrst patient
with IEDs, a 59 year-old Caucasian woman, displayed both
generalized and left temporal discharges. The second, a 61
year-old Caucasian woman, displayed independent bitem-
poral discharges and was subsequently admitted to the
Epilepsy Monitoring Unit. Prolonged video-monitored EEG
over 5 days for the second patient revealed intermittent
though clustered discharges of 4–5 Hz rhythmic theta activity
of 35–78 s in duration emanating from the T7 derivation with
sporadic spread to the P7 and O1/Oz derivations. During these
seizure discharges, the patient would display inattentiveness
and have difﬁculty operating her phone, though remained
aware and communicative. Both patients with IEDs were
clinically diagnosed with PCA. Importantly, neither patient
during the time of the EEG recording was taking medications
that may inﬂuence the EEG, including memantine [19].
4.3. Neuroimaging
Magnetic resonance imaging (MRI) and positron emission
tomography (PET) of the brain was performed in both patients
with IEDs. The ﬁrst described patient had a normal PET and
subtle biparietal atrophy on MRI, whereas the second patient
had biparietal hypometabolism on PET imaging and left
hippocampal sclerosis on MRI. Of the total cohort of 23
patients, 4 had focal regions of encephalomalacia (1 frontal, 2
occipital, 1 temporal). One of those with focal encephaloma-
lacia had a normal EEG.
4.4. Antiepileptic drugs
Of the 17 patients with an abnormal EEG, 3 were started on
AEDs following an initial EEG. The ﬁrst patient with IEDs was
started on phenytoin 300 mg daily. The second patient with
IEDs was started on lamotrigine 150 mg twice daily with
levetiracetam 1000 mg twice daily resulting in improvements
in the IEDs during the Epilepsy Monitoring United admission
alongwith subjective reports ofmemory improvement. A third
patient was prescribed lamotrigine 100 mg twice daily for
reasons which were retrospectively unclear.5. DiscussionIn our cohort of 23 clinically diagnosed or autopsy-conﬁrmed
patients with PCAwho underwent routine EEGmonitoring, we
found that 17 of the 23 (74%) had an abnormal EEG and 2 of the
23 (9%) had IEDs. The true incidence, prevalence and impact of
epileptic ﬁndings on EEG for neurodegenerative conditions are
unknown, although transient non-convulsive seizures or
epileptic amnesia would be expected to worsen cognitive
and other higher order functions [3,7]. Though our sample size
is small, our study raises a possibility that patients with PCA
may have a higher frequency of epileptic ﬁndings when
compared to prior studies of patients with typical AD [17].
Additionally, serial EEGs in the normal cohort may be of
beneﬁt because as the underlying neurodegenerative process
continues IEDsmay emerge [6]. If scalp EEG is unrevealing and
a strong clinical suspicion for dementia related epilepsy
remains, alternative electrode placement (e.g. foramen ovale)
may be of use to identify undetectable epileptic discharges due
to depth from the scalp [20]. Given the correlation with
abnormal EEG ﬁndings and worsened cognitive status, a more
liberal use of scalp EEGs in patients with dementia may be of
beneﬁt.
The second patient with IEDs, who ultimately underwent
prolonged video-monitored EEG, had clustered focal aware
seizures with cognitive features. Her neuroimaging and
clinical examination was suggestive of PCA though her brain
MRI revealed left hippocampal sclerosis. Her seizure focus
appeared to be of posterior temporal onset with a localized
ﬁeld of spread. It is well described that hippocampal sclerosis
may coexist with other neurodegenerative conditions, namely
AD, or may originate from a ‘‘dual pathology’’ as a result of
uncontrolled extra-temporal lobe epileptic seizures, of which
this patient may not have been aware [21,22].
AED usage in AD is sporadic and without consensus for
drug choice, though there is evidence to suggest that
levetiracetam and lamotrigine may provide the greatest
beneﬁt in terms of optimal tolerability, safety, and pharmaco-
kinetic balance [23]. We observed that a variety of AEDs were
used including phenytoin, levetiracetam, and lamotrigine.
Although this study was not designed to examine the effect of
AEDs on treatment of IEDs, in one patient with bitemporal
independent IEDs and focal aware seizures with cognitive
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in cognitive functioning. Data is available revealing a negative
correlation between burden of IED and global cognitive
function, which is in support of our patient's subjective
cognitive improvement [24]. Though the data is not conclusive,
we speculate whether early implementation of AEDs in this
select subset of AD patients may provide beneﬁt in short-term
morbidity.
Our study has several limitations. Due to the restricted
sample size both with IEDs and within the overall referral rate
of PCA patients with EEG evaluation, inferences regarding the
true prevalence of IEDs for patients with PCA cannot be made.
Referral bias is also of concern as those with EEGs were
typically referred with some level of concern for seizures.
Additionally, the lack of prolonged video-monitored EEG may
have inadvertently underestimated the prevalence of IEDs in
our cohort as the majority of those studied solely had
undergone a routine outpatient EEG, which is less sensitive
than prolonged (48–72 h) EEG recordings.
6. Clinical implications/future directionsOur ﬁndings suggest that those patients with PCA may have a
higher prevalence of IEDs which may provide a therapeutic
opportunity for the treating physician. Much is not known
regarding the beneﬁt, optimal therapy, and overall clinical
implications of treating patients with PCA with AEDs. Larger
prospective studies are required to further evaluate the impact
of IEDs on cognitive function, treatment response, and
preferential AED selection in patients with PCA speciﬁcally.
Further studies with quantitative EEG (qEEG) may aid in
understanding IED localization, frequency, and response to
treatment as well as possibly differentiating between other
subsets of neurodegeneration [25,26]. These studies may well
clarify the correlation of EEG ﬁndings to clinical phenotypes,
the role of AEDs and implementation of a guideline-directed
therapeutic algorithm in this patient population.
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